ESWL

EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary

Retrieved on: 
Tuesday, December 6, 2022
TMS, Silicon, NYSE, Annual report, ESWL, Security (finance), Prostate cancer, CFO, Intel, KLA, Silicon Graphics, Focal, Risk, KLAC, EDAP, Google Images, Organization, Growth, INTC, Laser, Hewlett-Packard, HPQ, COVID-19, Patient, Management, Medical imaging

LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company’s U.S. subsidiary.

Key Points: 
  • LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company’s U.S. subsidiary.
  • Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, “I am very pleased to welcome Ken onboard our U.S. subsidiary.
  • He brings over 25 years of financial leadership across all finance disciplines with extensive experience building strong relationships to drive operating results.
  • Prior to joining EDAP Technomed, Ken served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Incorporated (Nasdaq: ARAY), one of the leading radiation therapy companies in the industry.

EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Focal, EDAP, Google Images, Patient, Annual report, Trial of the century, ESWL, Security (finance), News, Laser, Risk, Endometriosis, TMS, Prostate cancer, Safety, Pharmaceutical industry, Medical imaging

LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French authorities to initiate a Phase 3 randomized, controlled clinical trial evaluating Focal One high intensity focused ultrasound (HIFU) as a potential treatment for rectal deep infiltrating endometriosis.

Key Points: 
  • Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, This is great news and a notable milestone for our Focal One HIFU endometriosis program.
  • This level 1 study the most rigorous trial design - is a multi-center, double blind, randomized, controlled clinical trial.
  • The study will enroll 60 subjects across eight centers in France, with 30 subjects randomized to each group.
  • The Company recently completed a Phase 2 study evaluating HIFU as a potential treatment for deep infiltrating endometriosis.

EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
Google Images, ESWL, TMS, Focal, Prostate cancer, Laser, EDAP, Sales, Medical imaging

Please contact your Piper Sandler representative if you would like to schedule a one-on-one meeting during the conference.

Key Points: 
  • Please contact your Piper Sandler representative if you would like to schedule a one-on-one meeting during the conference.
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

Retrieved on: 
Wednesday, November 2, 2022
HIFU, Prostate cancer, Google Images, TMS, Laser, ESWL, Company, EDAP, Focal, Medical imaging

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY23

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Prostate cancer, Annual report, Risk, U.S. Securities and Exchange Commission, Focal, Centers for Medicare & Medicaid Services, HIFU, Google Images, APC, Hospital, Nasdaq, CMS, COVID-19, ESWL, OPPS, TMS, Adoption, Laser, Company, Medicare, Patient, EDAP, Health insurance, Medical imaging

LYON, France, November 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has released its final outpatient prospective payment system (OPPS) reimbursement rule for calendar year 2023 (CY23), which becomes effective on January 1st.

Key Points: 
  • For a hospital performing a Focal One HIFU prostate ablation on an outpatient basis, the final rule increases the reimbursement level to an Ambulatory Payment Classification (APC) level 6, as compared to APC level 5 currently.
  • This represents an increase of more than 90% over the current reimbursement level.
  • We view this as a very positive step forward for the prostate cancer patients who can benefit from this novel therapy.
  • Ryan Rhodes, Chief Executive Officer of EDAP US, stated, This final rule change is a significant development in achieving appropriate reimbursement for facilities offering their patients a precise treatment with Focal One HIFU.

Global Stone Management Device (MedCore) Market Analysis Report 2022-2028: Focus on ESWL Equipment, Stone Management Laser, Stone Fragment Retrieval Device, Urethral Stent, Access Sheath - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health Technology, Health, Medical Devices, Holmium, BD (company), Average selling price, Data source name, Adoption, Ureter, COVID-19, Endoscopy, Cook Group, Ageing, Competitive analysis, FDA, Prevalence, Disruptive innovation, Conditional sentence, Population, Russian Industrial Leaders Index, Technology, ESWL, FDA recall policies, Windows Internal Database, SWOT, Boston Scientific, Mergers and acquisitions, Kidney, Coverage, CAGR, Video game, Medical imaging

The "Stone Management Device Market Size, Share & COVID-19 Impact Analysis | Global | 2022-2028 | MedCore" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stone Management Device Market Size, Share & COVID-19 Impact Analysis | Global | 2022-2028 | MedCore" report has been added to ResearchAndMarkets.com's offering.
  • The total global stone management device market is growing at a rate of 5.4%, which will take the 2021 market value of $1.1 billion up to $1.6 billion by 2028.
  • The full report suite on the global stone management device market includes extracorporeal shock wave lithotripsy (ESWL) capital equipment, holmium and thulium laser capital equipment and fibers, stone fragment retrieval devices, access sheaths and ureteral stents.
  • Overall, within the global stone management device market there are three dominant competitors: Boston Scientific, Cook Medical, and Becton Dickinson.

EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration

Retrieved on: 
Monday, September 26, 2022
Risk, COVID-19, TMS, Laser, Q&A, Company, Lithotripsy, EDAP, Focal, U.S. Securities and Exchange Commission, ESWL, Langham Hotel, London, Annual report, Nasdaq, Security (finance), Google Images, HIFU, Prostate cancer, Medical imaging

LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.

Key Points: 
  • LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.
  • Please join the company in-person or virtually as it hosts an event featuring:
    A Focal One Robotic focal HIFU introduction from EDAP's U.S. CEO
    A live Q&A session will follow the formal presentations.
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

The Worldwide Kidney Stone Retrieval Devices Industry is Expected to Reach $3.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022
Medical Devices, Health, Adoption, Time-invariant system, Incidence, COVID-19, Prevalence, Anesthesia, Growth, Lithotripsy, Kidney, USD, Patient, Investment, ESWL, Diagnosis, Research, Mergers and acquisitions, Boston Scientific, BD, Recurrence, CAGR, Pharmaceutical industry

Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.

Key Points: 
  • Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.
  • Considerably smaller ureter scopes, quartz fibers, and lithotripter probes have made the extraction of kidney stones from previously unreachable locations far safer than traditional surgical options.
  • For instance, the Dretler stone cone is one innovation that inhibits stone migration during the treatment.
  • The demand for kidney stone retrieval devices was uneven, with installation delays and a decline in manufacturing during the pandemic.

ADVANCED MEDTECH ACQUIRES WIKKON, STRENGTHENING ITS MARKET LEADING POSITION IN UROLOGY MEDICAL DEVICES

Retrieved on: 
Tuesday, September 13, 2022
Engineering, Erectile dysfunction, Name, Acquisition, Life, Medtech, Dornier, Industry, Kidney, Patient, Entrepreneurship, Ministry of Education (Malaysia), Physician, ESWL, Technology, Solution, Integration, Arthralgia, ESWT, Research, Dornier Flugzeugwerke, Urology, Lithotripsy, Fine chemical, Medical device, Medical imaging, Pharmaceutical industry, Video game console, Group, Temasek

Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.

Key Points: 
  • Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.
  • Abel Ang, Group Chief Executive of Advanced MedTech, said: We are now uniquely placed to aggressively grow in Chinas sizeable market, which is best served by domestically produced devices.
  • Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and contract manufacturing services.
  • Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world.

$1.87 Billion Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecasts, 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022
Medical Devices, Health, FDA, Woman, Fluoroscopy, Man, Risk, Medical device regulation, National Kidney Foundation, ESWL, Population, Technology, Growth, USD, CT, Incidence, Public employment services in the European Union, Prevalence, Urology, Coronary artery disease, Dornier, COVID-19, Kidney, Acquisition, Lithotripsy, Shock, Ageing, Chronic kidney disease, Awareness, Competitive landscape, CAGR, Plaque, Boston Scientific, US, Patient, Certification, Efficiency, MDR, Rock, Pharmaceutical industry, Medical imaging

The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Global Lithotripsy Devices Market was valued at USD 1.44 billion in 2021, growing at a CAGR of 4.35% during the forecast period from 2022 to 2027, to reach USD 1.87 billion by 2027.
  • Such technological advancement in the field of Lithotripsy Devices is likely to boost the Global Lithotripsy Devices Market during the forecast period.
  • Which are the regions and countries where companies should have concentrated on opportunities for Lithotripsy Devices market growth in the coming future?